EUVIMEDOdkrijte EUVIMED
Open access · CC BY-NC-ND 4.0

Is Preoperative Chemoprophylaxis Safe for Venous Thromboembolism Prevention in Patients With Head and Neck Cancer?

Heba Isaac, Mark A Arnold, Nitin A Pagedar, Marisa R Buchakjian, Kiranya E Arnold

Otolaryngology–Head and Neck Surgery · 2024

DOI: 10.1002/ohn.875 ↗

At a glance

Journal article in Otolaryngology–Head and Neck Surgery, 2024. Written by Heba Isaac and 4 co-authors. Institution: Department of Otolaryngology-Head and Neck Surgery, University of Iowa Hospitals and Clinics, Iowa City, USA. Major MEDLINE topics: Venous Thromboembolism, Head and Neck Neoplasms, Preoperative Care, Anticoagulants. Cited 1 times so far (Crossref); 46 references. The full text is freely available (open access, CC BY-NC-ND 4.0).

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Objective

To assess the safety of preoperative chemoprophylaxis (PEC) in head and neck cancer (HNC) patients undergoing oncologic procedures. Study Design Retrospective cohort study.

Setting

Tertiary academic center.

Methods

HNC patients with Caprini risk score (CRS) ≥5 who underwent inpatient surgery ≥3 hours between 2015 and 2020 were included. Patients were divided into 2 cohorts, PEC and control, based on whether or not they received a single dose of low molecular weight heparin or unfractionated heparin prior to surgery. The primary endpoint was the 30‐day rate of major bleeding events.

Results

A total of 539 patients were included; 427 patients received PEC prior to surgery. The rate of major bleeding was 6.7%. The PEC cohort was more likely to have received concurrent aspirin or ketorolac (225 of 427 patients vs 36 of 112 patients; P = .0002), greater duration of chemoprophylaxis (7.8 vs 5.0 days; P < .0001), have higher CRS (7.2 vs 6.6; P < .0001), longer operative times (596 vs 512 minutes; P < .0001), higher blood loss (265 vs 214 ml; P = .02), and higher bleeding rates when compared to the control (34 of 427 patients; P = .03). On multivariate analysis, only PEC was associated with bleeding (odds ratio, 8.74; 95% confidence interval, 1.15‐66.5). The rate of VTE was 1.3% and was not significantly different between cohorts.

Conclusion

PEC was associated with an increase in bleeding and did not result in lower rates of VTE in patients with HNC. This study highlights the need to determine the optimal regimen of chemoprophylaxis in this patient cohort. Level of Evidence 3

Subjects

MeSH terms (MEDLINE)

Venous ThromboembolismHead and Neck NeoplasmsPreoperative CareAnticoagulantsChemopreventionHumansMaleFemaleRetrospective StudiesMiddle AgedAgedAspirinHeparin, Low-Molecular-WeightHeparin

Author keywords

head and neck cancerpreoperative chemoprophylaxisthromboprophylaxisvenous thromboembolism

Substances

AnticoagulantsAspirinHeparin, Low-Molecular-WeightHeparin

Authors and institutions

  • Department of Otolaryngology-Head and Neck Surgery, University of Iowa Hospitals and Clinics, Iowa City, USA.
  • Department of Otolaryngology, SUNY Upstate, Syracuse, USA.

Cite

APA

Isaac, H., Arnold, M. A., Pagedar, N. A., Buchakjian, M. R., & Arnold, K. E. (2024). Is Preoperative Chemoprophylaxis Safe for Venous Thromboembolism Prevention in Patients With Head and Neck Cancer?. Otolaryngology–Head and Neck Surgery. https://doi.org/10.1002/ohn.875

Vancouver

Isaac H, Arnold MA, Pagedar NA, Buchakjian MR, Arnold KE. Is Preoperative Chemoprophylaxis Safe for Venous Thromboembolism Prevention in Patients With Head and Neck Cancer?. Otolaryngology–Head and Neck Surgery. 2024. doi:10.1002/ohn.875

BibTeX
@article{Isaac2024,
  author = {Isaac, Heba and Arnold, Mark A and Pagedar, Nitin A and Buchakjian, Marisa R and Arnold, Kiranya E},
  title = {Is Preoperative Chemoprophylaxis Safe for Venous Thromboembolism Prevention in Patients With Head and Neck Cancer?},
  journal = {Otolaryngology–Head and Neck Surgery},
  year = {2024},
  doi = {10.1002/ohn.875}
}
Start for free →